These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34365130)

  • 1. The antibacterial activity of fluoroquinolone derivatives: An update (2018-2021).
    Jia Y; Zhao L
    Eur J Med Chem; 2021 Nov; 224():113741. PubMed ID: 34365130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates of fluoroquinolones as antibacterial agents.
    Ezelarab HAA; Abbas SH; Hassan HA; Abuo-Rahma GEA
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800141. PubMed ID: 30048015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones: Blessings Or Curses.
    Majalekar PP; Shirote PJ
    Curr Drug Targets; 2020; 21(13):1354-1370. PubMed ID: 32564750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.
    Dalhoff A
    Infection; 2012 Jun; 40(3):239-62. PubMed ID: 22460782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ciprofloxacin and antibacterial therapy of respiratory tract infections].
    Ivanov DV; Budanov SV
    Antibiot Khimioter; 2006; 51(5):29-37. PubMed ID: 17310788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in quinolone hybrids with potential antibacterial activity against drug-resistant bacteria.
    Jun W; Yumin S; Heng Y
    Future Med Chem; 2023 Mar; 15(6):555-578. PubMed ID: 37102377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New fluoroquinolone compounds with endo-nortropine derivatives at C-7 position show antibacterial activity against fluoroquinolone-resistant strains of Staphylococcus aureus.
    Salunke RA; Shukla M; Kaul G; Bansal BR; Chopra S; Chhibber M
    Chem Biol Drug Des; 2019 Sep; 94(3):1626-1633. PubMed ID: 30860312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
    Rossolini GM
    Infez Med; 2009 Dec; 17 Suppl 5():5-12. PubMed ID: 20424531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
    Ellsworth EL; Tran TP; Showalter HD; Sanchez JP; Watson BM; Stier MA; Domagala JM; Gracheck SJ; Joannides ET; Shapiro MA; Dunham SA; Hanna DL; Huband MD; Gage JW; Bronstein JC; Liu JY; Nguyen DQ; Singh R
    J Med Chem; 2006 Nov; 49(22):6435-8. PubMed ID: 17064062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Quinolone hybrids and their antibacterial activities.
    Hu YQ; Zhang S; Xu Z; Lv ZS; Liu ML; Feng LS
    Eur J Med Chem; 2017 Dec; 141():335-345. PubMed ID: 29031077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Which partner for the betalactam agent in empiric combined therapy? I Fluoroquinolone].
    Bedos JP
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):636-8. PubMed ID: 15234734
    [No Abstract]   [Full Text] [Related]  

  • 16. The Antibacterial Activity of Isatin Hybrids.
    Liu B; Jiang D; Hu G
    Curr Top Med Chem; 2022; 22(1):25-40. PubMed ID: 34784867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fluoroquinolones in ophthalmology: mechanisms of action and resistance].
    Labetoulle M; Chiquet C
    J Fr Ophtalmol; 2008 Oct; 31(8):795-801. PubMed ID: 19107047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of antibacterial-like activity on a silica surface: fluoroquinolones and their environmental metabolites.
    Lewis G; Juhasz A; Smith E
    Environ Sci Pollut Res Int; 2011 Aug; 19(7):2795-801. PubMed ID: 22311580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
    Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
    PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus.
    Kerns RJ; Rybak MJ; Kaatz GW; Vaka F; Cha R; Grucz RG; Diwadkar VU; Ward TD
    Bioorg Med Chem Lett; 2003 May; 13(10):1745-9. PubMed ID: 12729656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.